News & Media

News Updates

INBS Announces Qabas as Exclusive Distributor in Saudi Arabia

Intelligent Bio Solutions Inc. Announces QabasTech as Exclusive Distributor in Saudi Arabia 

New York, July 24, 2024 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced QabasTech (“Qabas”) as its exclusive distributor in Saudi Arabia. This partnership marks further growth for INBS in the country, aligning with its ambitious infrastructure projects and commitment…

READ MORE >
INBS Advances FDA 510(k) Pathway with Biocompatibility Study

­­­Intelligent Bio Solutions Inc. Advances on FDA 510(k) Pathway with Biocompatibility Study Success

NEW YORK, 18 July, 2024 — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of biocompatibility testing of its Intelligent Fingerprinting Drug Screening System, a pivotal phase in the clinical study plan required for FDA 510(k) regulatory clearance. …

READ MORE >
INBS Strengthens UK Market Position with Addition of Key Manufacturing Accounts

Intelligent Bio Solutions Strengthens UK Market Position with Addition of Key Manufacturing Account

New York, July 9, 2024 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the addition of several key accounts in the UK manufacturing sector. This announcement follows recent successes in the warehouse and logistics, transport and infrastructure, and retail sectors…

READ MORE >
INBS Completes In-Clinic Portion of PK Study

Intelligent Bio Solutions Completes In-Clinic Portion of Pharmacokinetic (PK) Study Part of 510(k) Pathway for Approval & Commences Review of Results

New York, June 28, 2024 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of the in-clinic portion of its pharmacokinetic (PK) study, a core component of the Company’s clinical study plan for its 510(k) pathway for regulatory…

READ MORE >
INBS Expands Presence in the UK Retail Sector

Intelligent Bio Solutions Expands Presence in the UK Retail Sector with Major Account Acquisitions

New York, June 27, 2024 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the expansion of its customer network within the UK retail sector. This includes the adoption of INBS’ Intelligent Fingerprinting Drug Screening System by three prominent UK retailers, among the largest and…

READ MORE >
warehouse

Intelligent Bio Solutions Broadens UK Customer Base by Securing Two Key Accounts with Over 70 Locations and Over 15,000 Employees in the Warehouse and Logistics Sector

New York, June 20, 2024 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it has successfully signed two new major customer accounts within the UK warehouse and logistics sector within the past three months. These accounts employ more than…

READ MORE >
pharmacokenetic

Intelligent Bio Solutions Begins Subject Dosing and Sampling for FDA 510(k) Pharmacokinetic (PK) Study for its Intelligent Fingerprinting Drug Screening Technology

New York, June 18, 2024 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it is entering the next phase of its planned 510(k) submission to the FDA. The Company has successfully completed subject screening for its Pharmacokinetic (PK) Study…

READ MORE >
INBS Implements Strategic Reorganization Plan to Support Global Growth

Intelligent Bio Solutions Implements Strategic Reorganization Plan to Support Global Growth Initiatives

New York, June 13, 2024 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the implementation of a strategic and comprehensive reorganization and productivity plan to support the Company’s global growth initiatives. As the Company approaches several growth initiatives globally, including…

READ MORE >
INBS Adds Major EU Transport & Infrastructure Solutions Provider

Intelligent Bio Solutions Adds Major European Transport and Infrastructure Solutions Provider to Growing Number of Accounts Adopting Fingerprint Drug Screening Technology 

New York, June 12, 2024 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the addition of a major European transport and infrastructure solutions provider to its growing number of accounts. The company is using INBS’ Intelligent Fingerprinting Drug Screening System…

READ MORE >
INBS Completes Recruitment for FDA 510(k) PK Study

­­­Intelligent Bio Solutions Successfully Completes Recruitment and Begins Subject Screening for FDA 510(k) Pharmacokinetic (PK) Study

NEW YORK, May 29, 2024 — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful recruitment and commencement of screening for subjects in its pharmacokinetic (PK) study, a critical component of the Company’s FDA 510(k) regulatory pathway for clearance. Harry…

READ MORE >
INBS Unveils Key Performance Indicator Growth in the UK

Intelligent Bio Solutions Unveils Key Performance Indicator Growth in the United Kingdom as Drug Screening Industry Combats Drug Test Cheating and Searches for Simpler, Faster, Non-Invasive and More Cost-Effective Solutions

NEW YORK, May 23, 2024 — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today unveiled key performance indicators from its United Kingdom operations. These indicators have contributed to the Company’s growth as the drug screening industry continues to combat drug test cheating…

READ MORE >
Fingerprint Drug Test Showcased at Premier Health & Safety Event

Innovative Fingerprint Drug Screening Solution Showcased at the UK’s Premier Health and Safety Event

NEW YORK, May 17, 2024 — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful exhibition of its Intelligent Fingerprinting Drug Screening Solution at The Health & Safety Event 2024, the United Kingdom’s largest annual technology showcase exhibiting products and…

READ MORE >
INBS Reports Fiscal Q3 and 9-Month Financial Results

Intelligent Bio Solutions Inc. Reports Fiscal 2024 Third Quarter and Nine-Month Financial Results and Operational Highlights

NEW YORK, May 8, 2024 — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for the fiscal third quarter and nine months ended March 31, 2024, and provided a business update.     “We are pleased to report our third consecutive quarter of strong…

READ MORE >
INBS Preliminary Unaudited Fiscal Q3 Revenue Results

Intelligent Bio Solutions Inc. Announces Preliminary Unaudited Fiscal Third Quarter and Nine-Month Revenue Results

NEW YORK, April 18, 2024 — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced preliminary unaudited revenue results for the fiscal third quarter and nine months ended March 31, 2024. The Company expects approximate unaudited revenue of $0.82 million for the three months ended…

READ MORE >

Media

Media Contact

Sign Up

Subscribe to receive the latest news and updates from Intelligent Bio Solutions.